Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12064364 | 0.90 | CYP17A1 (0.47) | CYP17A1CD274NAMPTHDAC1HDAC6 | |
| SCHEMBL1109492 | 0.90 | CYP17A1 (0.53) | CYP17A1NAMPTHDAC1HDAC6HDAC3 | |
| SCHEMBL1095624 | 0.88 | NAMPT (0.42) | NAMPT | |
| SCHEMBL13818551 | 0.84 | HDAC1 (0.51) | NAMPTHDAC1HDAC6HDAC3HDAC10 | |
| SCHEMBL1109105 | 0.83 | HDAC4 (0.45) | CD274HDAC1HDAC6HDAC3HDAC10 | |
| SCHEMBL12064336 | 0.83 | HDAC4 (0.45) | CD274HDAC1HDAC6HDAC3HDAC10 | |
| SCHEMBL1105490 | 0.83 | PPARG (0.41) | CD274HDAC1HDAC6HDAC3HDAC10 | |
| SCHEMBL5450568 | 0.83 | CA2 (0.49) | — | |
| SCHEMBL405181 | 0.83 | CA2 (0.49) | — | |
| SCHEMBL13659472 | 0.82 | KIF11 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153843-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2012-04-10 | — | — | US | disclosed |
| US-8101640-B2 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-7989660-B2 | BACTERICIDE AGAINST GRAMNEGATIVE BACTERIA; RESPIARATORY SYSTEM DISORDERS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110172174-A1 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2011-07-14 | — | — | US | disclosed |
| US-20100324025-A1 | Antibacterial Agents | UNIVERSITY OF WASHINGTON (US) | 2010-12-23 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244197-A1 | Antibacterial agents | MRPL21, SI, PGLS | CYP17A1 1104/4885CD274 4420/4885NAMPT 1048/4885 |
| US-20110172174-A1 | Antibacterial agents | MRPL21, SI, PGLS | CYP17A1 1104/4885CD274 4420/4885NAMPT 1048/4885 |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | CYP17A1 1104/4885CD274 4420/4885NAMPT 1048/4885 |
| US-20100324025-A1 | Antibacterial Agents | MRPL21, SI, PGLS | CYP17A1 1104/4885CD274 4420/4885NAMPT 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.